Drug Trial Radar · NCT02101957
Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)
Last checked: Nov 19, 2026Latest source record: Apr 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
96
Actual
Start
Oct 2010
Primary completion
Jul 2015
Sponsor
- Lead sponsor
- University Hospital, AngersGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Apr 2, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of cysteamine in patients with symptomatic Huntington's disease by comparing two groups of patients (cysteamine vs placebo) on the results of the Unified Huntington's Disease Rating Scale (UHDRS, Huntington study group 1996).
Conditions
- Huntington's Disease
Interventions
RP103Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Unified Huntington's Disease Rating Scale motorTime frame: at 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHU Angers
Angers, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.